Interpretation
Albuminuria, CKD, albuminuria
Empagliflozin slowed the rate of progression of CKD among all types
of participant in the EMPA-KIDNEY trial, including those with little
albuminuria. Albuminuria alone should not be used to determine whether to
treat with an SGLT2i.